Chwilio Deddfwriaeth

Chwiliad Uwch

Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria (notified under document C(2013) 7145) (Text with EEA relevance) (2013/652/EU)

Help about what version

Pa Fersiwn

Help about advanced features

Nodweddion Uwch

Help about UK-EU Regulation

Deddfwriaeth yn deillio o’r UE

Pan adawodd y DU yr UE, cyhoeddodd legislation.gov.uk ddeddfwriaeth yr UE a gyhoeddwyd gan yr UE hyd at ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.). Ar legislation.gov.uk, mae'r eitemau hyn o ddeddfwriaeth yn cael eu diweddaru'n gyson ag unrhyw ddiwygiadau a wnaed gan y DU ers hynny.

Close

Mae'r eitem hon o ddeddfwriaeth yn tarddu o'r UE

Mae legislation.gov.uk yn cyhoeddi fersiwn y DU. Mae EUR-Lex yn cyhoeddi fersiwn yr UE. Mae Archif Gwe Ymadael â’r UE yn rhoi cipolwg ar fersiwn EUR-Lex o ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.).

Changes over time for: Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria (notified under document C(2013) 7145) (Text with EEA relevance) (2013/652/EU) (Annexes only)

Help about opening options

Changes to legislation:

There are currently no known outstanding effects by UK legislation for Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria (notified under document C(2013) 7145) (Text with EEA relevance) (2013/652/EU). Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

ANNEXU.K. TECHNICAL REQUIREMENTS

PART AU.K. SAMPLING FRAMEWORK AND ANALYSIS

1.Origin of isolatesU.K.

[F1The appropriate authority must] collect representative isolates for monitoring AMR from at least each of the following animal populations and food categories:

Textual Amendments

(a)

Salmonella spp. isolates from:

(i)

each population of laying hens, broilers and fattening turkeys sampled in the framework of the F2... control programmes, established in accordance with Article 5(1) of Regulation (EC) No 2160/2003;

(ii)

carcases of both broilers and fattening turkeys sampled for testing and verification of compliance, in accordance with point 2.1.5 of Chapter 2 of Annex I to Regulation (EC) No 2073/2005;

(iii)

carcases of fattening pigs sampled for testing and verification of compliance, in accordance with point 2.1.4 of Chapter 2 of Annex I to Regulation (EC) No 2073/2005;

(iv)

carcases of bovines under one year of age where the production of meat of those bovines in the [F3United Kingdom] is more than 10 000 tonnes slaughtered per year sampled for testing and verification of compliance, in accordance with point 2.1.3 of Chapter 2 of Annex I to Regulation (EC) No 2073/2005.

(b)

C. jejuni isolates from caecal samples gathered at slaughter from broilers and from fattening turkeys where the production of turkey meat in the [F4United Kingdom] is more than 10 000 tonnes slaughtered per year.

(c)

Indicator commensal E. coli isolates from:

(i)

caecal samples gathered at slaughter from broilers and from fattening turkeys where the production of turkey meat in the [F4United Kingdom] is more than 10 000 tonnes slaughtered per year;

(ii)

caecal samples gathered at slaughter from fattening pigs and bovines under one year of age where the production of meat of those bovines in the [F4United Kingdom] is more than 10 000 tonnes slaughtered per year.

(d)

ESBL- or AmpC- or carbapenemase-producing E. coli from:

(i)

caecal samples gathered at slaughter from broilers and from fattening turkeys where the production of turkey meat in the [F4United Kingdom] is more than 10 000 tonnes slaughtered per year;

(ii)

caecal samples gathered at slaughter from fattening pigs and bovines under one year of age where the production of meat of those bovines in the [F4United Kingdom] is more than 10 000 tonnes slaughtered per year;

(iii)

samples of fresh meat of broilers, pig meat and bovine meat gathered at retail.

(e)

Where [F5the appropriate authority] decides to test C. coli in accordance with Article 2(3)(a), isolates from:

(i)

caecal samples gathered at slaughter from broilers;

(ii)

caecal samples gathered at slaughter from fattening pigs.

(f)

Where [F6the appropriate authority] decides to test E. faecalis and E. faecium in accordance with Article 2(3)(b), isolates from:

(i)

caecal samples gathered at slaughter from broilers and from fattening turkeys where the production of turkey meat in the [F7United Kingdom] is more than 10 000 tonnes slaughtered per year;

(ii)

caecal samples gathered at slaughter from fattening pigs and bovines under one year of age where the production of meat of those bovines in the [F8United Kingdom] is more than 10 000 tonnes slaughtered per year.

Textual Amendments

Isolates obtained by the [F9appropriate authority] from an origin other than those referred to in points (a) to (f), may be tested for AMR by the competent authority on a voluntary basis and kept separately when reported in accordance with point 2 of Part B of the Annex. However, when carrying out such testing for AMR, the specific technical requirements of points 3, 4 and 5 shall apply.

Textual Amendments

2. Sampling frequency, size and design U.K.

2.1.Sampling frequencyU.K.

[F10The appropriate authority must] carry out every two years the sampling, the collection and the antimicrobial susceptibility testing provided for in Article 2 to 4 of each combination of bacterial species and type of sample of animal populations or food categories listed in point 1 of this Part and the specific monitoring of ESBL- or AmpC- or carbapenemase-producing Salmonella spp. and E. coli in accordance with point 4 of this Part in accordance with the following rotation system:

Textual Amendments

(a)

In the years 2014, 2016, 2018 and 2020 for laying hens, broilers and fresh meat thereof, and fattening turkeys. However, the specific monitoring of ESBL- or AmpC- or carbapenemase-producing indicator commensal E. coli in accordance with point 4.1 shall not be mandatory in the year 2014;

(b)

In the years 2015, 2017 and 2019, for pigs, bovines under one year of age, pig meat and bovine meat.

2.2.Sample sizeU.K.

[F11The appropriate authority must] test 170 isolates for antimicrobial susceptibility testing for each combination of bacterial species and type of sample of animal population or food category listed in point 1(a), (b), (c), (e) and (f). However, [F12if there is] a production of less than 100 000 tonnes of poultry meat slaughtered per year and less than 100 000 tonnes of pig meat slaughtered per year(1) [F13in the United Kingdom], [F14its] shall test 85 isolates instead of 170 isolates for each corresponding specific combination.

Textual Amendments

[F15If], in any given year, a higher number of isolates for some of the combinations of bacterial species and type of sample of animal population or food category listed in point 1(a), (b), (c), (e) and (f) is available, all isolates or a representative random selection equal to or greater than the number of isolates required in accordance with the first paragraph, shall be included in the antimicrobial susceptibility testing.

Textual Amendments

[F15If], due to a low bacterial prevalence or low number of epidemiological units, in any given year, the number of isolates required in accordance with the first paragraph for some of the combinations of bacterial species and type of sample of animal population or food category listed in point 1(a), (b), (c), (e) and (f), cannot be achieved, all available isolates at the end of the monitoring period shall be included in the antimicrobial susceptibility testing.

For the specific monitoring of ESBL- or AmpC- or carbapenemase-producing indicator commensal E. coli set out in point 4.1, [F16the appropriate authority must] analyse 300 samples of each of the animal population and food category, listed in point 1(d). However, [F17if there is] a production of less than 100 000 tonnes of poultry meat slaughtered per year, less than 100 000 tonnes of pig meat slaughtered per year and less than 50 000 tonnes bovine meat slaughtered per year(2) [F18in the United Kingdom] the [F16the appropriate authority must] analyse 150 samples instead of 300 samples for each corresponding specific combination.

Textual Amendments

2.3.Sampling designU.K.

Isolates which are tested for antimicrobial susceptibility as provided for in Article 2 shall be obtained from monitoring programmes, based on randomised sampling design. The bacterial isolates referred to in Article 2 must originate from randomly selected epidemiological units or randomly selected within the slaughterhouses. Where diseased animals are sampled, the result of the antimicrobial susceptibility testing shall be kept separately when reported in accordance with point 2 of Part B.

The competent authority shall ensure the randomisation of the sampling scheme and its correct implementation.

In the case of sampling at slaughterhouses as provided for in point 1 of Part A, sampling shall be performed at slaughterhouses processing at least 60 % of the specific domestic animal population in the [F19United Kingdom], starting with the slaughterhouses of largest throughput.

Textual Amendments

Not more than one isolate per bacterial species from the same epidemiological unit per year shall be included in the monitoring provided for this Decision. The epidemiological unit for laying hens, broilers, and fattening turkeys shall be the flock. For fattening pigs and bovines under one year of age, the epidemiological unit shall be the holding.

2.3.1.Representative sampling of samples at slaughterU.K.

The random sampling plan shall be stratified per slaughterhouse by allocating the number of samples from domestically produced animals collected per slaughterhouse proportionally to the annual throughput of the slaughterhouse.

The collected samples at slaughter shall be evenly distributed over each month of the year to enable the different seasons to be covered.

Only one representative sample of caecal content per epidemiological unit, derived either from a unique carcass or from a number of carcasses, shall be gathered to account for clustering. The sampling shall otherwise be based on a random selection regarding sampling days each month and which batches are to be sampled on a selected sampling day.

The number of biological samples to be collected in accordance with point 1(a), (b), (c), (e) and (f) of Part A shall be determined in order to achieve the required number of isolates by accounting for the prevalence of the bacteria species monitored.

2.3.2.Collection of representative Salmonella spp. isolates collected in the framework of the F20... control programmes for Salmonella spp. in relevant animal populations and in the framework of Regulation (EC) No 2073/2005U.K.

Antimicrobial susceptibility testing shall be carried out for no more than one isolate per Salmonella serovar from the same epidemiological unit per year.

Where the number of Salmonella isolates yearly available per animal population in the [F21United Kingdom] is higher than the number of isolates required in accordance with point 2.2, a random selection of at least 170 or 85 isolates shall be performed from the collection of yearly available isolates in the [F21United Kingdom], in a way that ensures geographical representativeness and an even distribution of the date of sampling over the year. Conversely, in the case of a low prevalence, all the Salmonella isolates available shall be tested for susceptibility.

Textual Amendments

Textual Amendments

2.3.3.Collection of samples at retailU.K.

[F22The appropriate authority must] collect at retail random samples of fresh meat of broilers, pig meat and bovine meat without pre-selecting samples based on the origin of the food.

Textual Amendments

3.Antimicrobials for susceptibility testing, epidemiological cut-off values and concentration ranges to be used for antimicrobial susceptibility testing of the isolatesU.K.

[F23The appropriate Minister must] test the antimicrobials and interpret the results using the epidemiological cut-off values and the concentration ranges that are set out in Tables 1, 2 and 3, to determine the susceptibility of Salmonella spp., C. coli, C. jejuni, indicator commensal E. coli, E. faecalis and E. faecium.

Textual Amendments

Dilution methods shall be performed according to the methods described by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), accepted as the international reference method (ISO standard 20776-1:2006).

Table 1

Panel of antimicrobial substances to be included in AMR monitoring, EUCAST thresholds for resistance and concentration ranges to be tested in Salmonella spp. and indicator commensal E. coli (First panel)

a

EUCAST epidemiological cut-off values.

b

EUCAST clinical resistance breakpoints.

c

Data from EUCAST available for Salmonella Enteriditis, Typhimurium, Typhi and Paratyphi.

NA

:

not available.

AntimicrobialSpeciesInterpretative thresholds of AMR(mg/L)Range of concentrations (mg/L)(No of wells in brackets)
ECOFFaClinical breakpointb
AmpicillinSalmonella> 8> 81-64 (7)
E. coli> 8> 8
CefotaximeSalmonella> 0,5> 20,25-4 (5)
E. coli> 0,25> 2
CeftazidimeSalmonella> 2> 40,5-8 (5)
E. coli> 0,5> 4
MeropenemSalmonella> 0,125> 80,03-16 (10)
E. coli> 0,125> 8
Nalidixic acidSalmonella> 16NA4-128 (6)
E. coli> 16NA
CiprofloxacinSalmonella> 0,064> 10,015-8 (10)
E. coli> 0,064> 1
TetracyclineSalmonella> 8NA2-64 (6)
E. coli> 8NA
ColistinSalmonella> 2> 21-16 (5)
E. coli> 2> 2
GentamicinSalmonella> 2> 40,5-32 (7)
E. coli> 2> 4
TrimethoprimSalmonella> 2> 40,25-32 (8)
E. coli> 2> 4
SulfamethoxazoleSalmonellaNANA8-1 024 (8)
E. coli> 64NA
ChloramphenicolSalmonella> 16> 88-128 (5)
E. coli> 16> 8
AzithromycinSalmonellaNANA2-64 (6)
E. coliNANA
TigecyclineSalmonella> 1c> 2c0,25-8 (6)
E. coli> 1> 2

Table 2

Panel of antimicrobial substances to be included in AMR monitoring, EUCAST interpretative thresholds for resistance and concentration ranges to be tested in C. jejuni and C. coli

a

EUCAST epidemiological cut-off values.

b

EUCAST clinical resistance breakpoints.

c

At a voluntary basis.

NA

:

not available.

AntimicrobialSpeciesInterpretative thresholds of AMR(mg/L)Range of concentrations (mg/L)(No of wells in brackets)
ECOFFaClinical breakpointb
ErythromycinC. jejuni> 4> 41-128 (8)
C. coli> 8> 8
CiprofloxacinC. jejuni> 0,5> 0,50,12-16 (8)
C. coli> 0,5> 0,5
TetracyclineC. jejuni> 1> 20,5-64 (8)
C. coli> 2> 2
GentamicinC. jejuni> 2NA0,12-16 (8)
C. coli> 2NA
Nalidixic acidC. jejuni> 16NA1-64 (7)
C. coli> 16NA
StreptomycincC. jejuni> 4NA0,25-16 (7)
C. coli> 4NA

Table 3

Panel of antimicrobial substances to be included in AMR monitoring, EUCAST thresholds for resistance and concentration ranges to be tested in E. faecalis and E. faecium

a

EUCAST epidemiological cut-off values.

b

EUCAST clinical resistance breakpoints.

NA

:

not available.

AntimicrobialSpeciesInterpretative thresholds of AMR(mg/L)Range of concentrations (mg/L)(No of wells in brackets)
ECOFFaClinical breakpointb
GentamicinE. faecalis> 32NA8-1 024 (8)
E. faecium> 32NA
ChloramphenicolE. faecalis> 32NA4-128 (6)
E. faecium> 32NA
AmpicillinE. faecalis> 4> 80,5-64 (8)
E. faecium> 4> 8
VancomycinE. faecalis> 4> 41-128 (8)
E. faecium> 4> 4
TeicoplaninE. faecalis> 2> 20,5-64 (8)
E. faecium> 2> 2
ErythromycinE. faecalis> 4NA1-128 (8)
E. faecium> 4NA
Quinupristin/DalfopristinE. faecalisNANA0,5-64 (8)
E. faecium> 1> 4
TetracyclineE. faecalis> 4NA1-128 (8)
E. faecium> 4NA
TigecyclineE. faecalis> 0,25> 0,50,03-4 (8)
E. faecium> 0,25> 0,5
LinezolidE. faecalis> 4> 40,5-64 (8)
E. faecium> 4> 4
DaptomycinE. faecalis> 4NA0,25-32 (8)
E. faecium> 4NA
CiprofloxacinE. faecalis> 4NA0,12-16 (8)
E. faecium> 4NA

4.Specific monitoring of ESBL- or AmpC- or carbapenemase-producing Salmonella and E. coli U.K.

4.1.Method for detection of ESBL- or AmpC- or carbapenemase-producing E. coli in broilers, fattening turkeys, fattening pigs, bovines under one year of age and fresh meat of broilers, pig meat and bovine meatU.K.

For the purpose of estimating the proportion of samples containing ESBL- or AmpC- or carbapenemase-producing E. coli amongst the caecal samples collected from broilers, fattening turkeys, fattening pigs, bovines under one year of age, fresh meat of broilers, pig meat and bovine meat in accordance with point 1(d) of this Part, the following method shall apply.

For the detection of ESBL- or AmpC-producing E. coli the method shall start by a pre-enrichment step, followed by inoculation on McConkey agar containing a third generation cephalosporin in a selective concentration according to the most recent version of the detailed protocol for standardisation of the European Union Reference Laboratory for Antimicrobial Resistance(3). The microbial species E. coli shall be identified using an appropriated method.

The [F24appropriate authority] may decide, based on the epidemiological circumstances, to test in parallel an additional selective plate that inhibits for the growth of AmpC-producing E. coli to facilitate the specific detection of ESBL-producing E. coli. When using this possibility, the results of the additional selective plate that inhibits for growth of AmpC-producing E. coli shall be kept separately when reported in accordance with point 2 of Part B.

Textual Amendments

[F25The appropriate authority] may decide to detect for carbapenemase-producing micro-organisms by using selective pre-enrichment and subsequent selective plating on carbapenem-containing media, according to the most recent version of the detailed protocol for standardisation of the European Union Reference Laboratory for AMR(4).

Textual Amendments

One presumptive ESBL- or AmpC- or carbapenemase-producing E. coli isolate obtained from each positive caecal sample and meat sample shall be tested on the first panel of antimicrobials in accordance with Table 1 and further submitted to extended susceptibility testing as set out in point 4.2 if they are resistant to cefotaxime or ceftazidime or meropenem based on the interpretative criteria (epidemiological cut-off values) listed in Table 1.

4.2. Method for further characterisation and classification of Salmonella spp. and E. coli isolates showing resistance to third-generation cephalosporins or meropenem U.K.

All presumptive ESBL- or AmpC- or carbapenemase-producing E. coli isolates identified through the selective plating described in point 4.1 as well as all those randomly selected isolates of Salmonella spp. and E. coli that after testing with the first panel of antimicrobials in accordance with Table 1, are resistant to cefotaxime or ceftazidime or meropenem, shall be further tested with a second panel of antimicrobial substances in accordance with Table 4. This panel includes cefoxitin, cefepime and clavulanate synergy test in combination with cefotaxime and ceftazidime for detection of ESBL and AmpC production. In addition the second panel also contains imipenem, meropenem and ertapenem to phenotypically verify the presumptive carbapenemase-producers.

Table 4

Panel of antimicrobial substances, EUCAST epidemiological cut-off values (ECOFFs) and clinical resistance breakpoints and concentrations ranges to be used for testing only Salmonella spp. and indicator commensal E. coli isolates resistant to cefotaxime or ceftazidime or meropenem — (Second panel)

a

EUCAST epidemiological cut-off values.

b

EUCAST clinical resistance breakpoints.

c

4 mg/L clavulanic acid.

d

The values shall be compared to the values of Cefotaxime and Ceftazidime and interpreted according to CLSI or EUCAST guidelines regarding synergy testing.

NA

:

not available.

AntimicrobialSpeciesInterpretative thresholds of AMR(mg/L)Range of concentrations (mg/L)(No of wells in brackets)
ECOFFaClinical breakpointb
CefoxitinSalmonella> 8NA0,5-64 (8)
E. coli> 8NA
CefepimeSalmonellaNANA0,06-32 (10)
E. coli> 0,125> 4
Cefotaxime + clavulanic acidcSalmonellaNAdNAd0,06-64 (11)
E. coliNAdNAd
Ceftazidime + clavulanic acidcSalmonellaNAdNAd0,125-128 (11)
E. coliNAdNAd
MeropenemSalmonella> 0,125> 80,03-16 (10)
E. coli> 0,125> 8
TemocillinSalmonellaNANA0,5-64 (8)
E. coliNANA
ImipenemSalmonella> 1> 80,12-16 (8)
E. coli> 0,5> 8
ErtapenemSalmonella> 0,06> 10,015-2 (8)
E. coli> 0,06> 1
CefotaximeSalmonella> 0.5> 20,25-64 (9)
E. coli> 0,25> 2
CeftazidimeSalmonella> 2> 40,25-128 (10)
E. coli> 0,5> 4

4.3.Quantitative method to assess the proportion of ESBL- or AmpC-producing E. coliU.K.

[F26The appropriate authority] may characterise the proportion of ESBL- or AmpC-producing E. coli within the whole E. coli population.

Textual Amendments

That shall be done by enumerating ESBL- or AmpC-producing E. coli and total E. coli present in a sample using dilution methods and subsequent plating onto selective media and non-selective media, according to the most recent version of the detailed protocol of the European Union Reference Laboratory for Antimicrobial Resistance(5).

5.Quality control and storage of the isolatesU.K.

The laboratories designated by the competent authority to perform the antimicrobial susceptibility testing of the isolates included in the F27... monitoring programme, shall be involved in a quality assurance system including proficiency test set up [F28at national level], in identification, typing and susceptibility testing of the bacteria targeted by the F27... monitoring of AMR.

Textual Amendments

Isolates shall be stored by the national reference laboratories for AMR at a temperature of – 80 °C for a minimum period of five years. Other methods of storage may alternatively be used provided that they ensure viability and absence of changes in strain properties.

PART BU.K.REPORTING

1.General provisions for reporting of the dataU.K.

Where AMR monitoring is performed by the competent authority from isolates obtained by a competent authority at other stages of the food chain than the ones referred to in point 1 of part A, but in accordance with the technical specifications referred to in points 3, 4 and 5 of part A, the results of this AMR monitoring shall be reported according to point 2 of this Part but they shall be kept separately reported and this will not change the number of isolates to be tested according to point 2 of Part A.

2.Information to be included for each individual sampleU.K.

Reports shall be made including the information referred to in points 2.1 to 2.6 for each individual isolate, considering separately each bacterial species and animal population combination and bacterial species and food combination referred to in point 1 of Part A.

F29...

Textual Amendments

2.1.Overall description of the implementation of the AMR monitoringU.K.

  • Description of sampling designs, stratification and randomisation procedures per animal populations and food categories.

2.2.General informationU.K.

  • Identifier or code of the isolate

  • Bacterial species

  • Serovar (for Salmonella spp.)

  • Phage type of Salmonella Enteriditis and Salmonella Typhimurium (optional)

2.3.Specific information with regard to the samplingU.K.

  • Food-producing animal population or food category

  • Stage of sampling

  • Type of sample

  • Sampler

  • The sampling strategy

  • Date of sampling

  • Date of isolation

2.4.Specific information with regard to antimicrobial resistance testingU.K.

  • Identifier or code of the isolate given by the laboratory performing the antimicrobial susceptibility testing of the isolate

  • Date of susceptibility testing

  • Antimicrobial substance

2.5.Specific information with regard to dilution method resultsU.K.

  • Minimum Inhibitory Concentration (MIC) value (in mg/L)

2.6.Synergy testing resultsU.K.

  • Synergy testing with clavulanic acid for ceftazidime

  • Synergy testing with clavulanic acid for cefotaxime

(1)

According to the most recent data available at Eurostat (http://epp.eurostat.ec.europa.eu).

(2)

See footnote 1.

(3)

www.crl-ar.eu

(4)

See footnote 3.

(5)

See footnote 3.

Yn ôl i’r brig

Options/Cymorth

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Gweler y wybodaeth ychwanegol ochr yn ochr â’r cynnwys

Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted version that was used for the EU Official Journal
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.

Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.

Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill

Mae'r data ar y dudalen hon ar gael yn y fformatau data amgen a restrir: